PortalPublikationenAllogeneic stem cell transplantation after conditioning with...

Allogeneic stem cell transplantation after conditioning with treosulfan, etoposide and cyclophosphamide for patients with ALL: a phase II-study on behalf of the German Cooperative Transplant Study Group and ALL Study Group (GMALL)

Standard

Allogeneic stem cell transplantation after conditioning with treosulfan, etoposide and cyclophosphamide for patients with ALL: a phase II-study on behalf of the German Cooperative Transplant Study Group and ALL Study Group (GMALL). / Kröger, Nicolaus ; Bornhäuser, M; Stelljes, M; Pichlmeier, U; Trenschel, R; Schmid, C; Arnold, R; Martin, H; Heinzelmann, M; Wolschke, C; Meyer, R G; Bethge, W; Kobbe, G; Ayuketang, Francis Ayuk; Gökbuget, N; Hölzer, D; Zander, A; Beelen, D.

in: BONE MARROW TRANSPL, Jahrgang 50, Nr. 12, 12.2015, S. 1503-7.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Kröger, N, Bornhäuser, M, Stelljes, M, Pichlmeier, U, Trenschel, R, Schmid, C, Arnold, R, Martin, H, Heinzelmann, M, Wolschke, C, Meyer, RG, Bethge, W, Kobbe, G, Ayuketang, FA, Gökbuget, N, Hölzer, D, Zander, A & Beelen, D 2015, 'Allogeneic stem cell transplantation after conditioning with treosulfan, etoposide and cyclophosphamide for patients with ALL: a phase II-study on behalf of the German Cooperative Transplant Study Group and ALL Study Group (GMALL)', BONE MARROW TRANSPL, Jg. 50, Nr. 12, S. 1503-7. https://doi.org/10.1038/bmt.2015.202

APA

Kröger, N., Bornhäuser, M., Stelljes, M., Pichlmeier, U., Trenschel, R., Schmid, C., Arnold, R., Martin, H., Heinzelmann, M., Wolschke, C., Meyer, R. G., Bethge, W., Kobbe, G., Ayuketang, F. A., Gökbuget, N., Hölzer, D., Zander, A., & Beelen, D. (2015). Allogeneic stem cell transplantation after conditioning with treosulfan, etoposide and cyclophosphamide for patients with ALL: a phase II-study on behalf of the German Cooperative Transplant Study Group and ALL Study Group (GMALL). BONE MARROW TRANSPL, 50(12), 1503-7. https://doi.org/10.1038/bmt.2015.202

Vancouver

Kröger N, Bornhäuser M, Stelljes M, Pichlmeier U, Trenschel R, Schmid C et al. Allogeneic stem cell transplantation after conditioning with treosulfan, etoposide and cyclophosphamide for patients with ALL: a phase II-study on behalf of the German Cooperative Transplant Study Group and ALL Study Group (GMALL). BONE MARROW TRANSPL. 2015 Dez;50(12):1503-7. https://doi.org/10.1038/bmt.2015.202

Bibtex

@article{e82a4607630b4aeb99c57dddc88e537b,
title = "Allogeneic stem cell transplantation after conditioning with treosulfan, etoposide and cyclophosphamide for patients with ALL: a phase II-study on behalf of the German Cooperative Transplant Study Group and ALL Study Group (GMALL)",
abstract = "TBI-based preparative regimens are considered as standard conditioning therapy for allogeneic stem cell transplantation (AHSC) in patients with ALL. We investigated toxicity and efficacy of a non-TBI-based regimen consisting of treosulfan, etoposide and cyclophosphamide for ALL within a prospective study. Major inclusion criteria were CR and non-eligibility for TBI. Fifty patients with a median age of 46.5 years (range, 18-64) were included. Donors were HLA-identical sibling (n=8), matched (n=42) or mismatched (n=10) unrelated. The toxicity was moderate, resulting in a cumulative incidence of non-relapse mortality (NRM) at 1 year of 8% (90% confidence interval: 2-15%). Acute GvHD grade II-IV and grade III/IV was noted in 53% and 14%, respectively. Chronic GvHD at one year was seen in 41%. After a median follow-up of 24 months the cumulative incidence of relapse was 36% (90% confidence interval: 24-48) and 51% (90% confidence interval: 37-65) at 1 and 2 years, respectively. The estimated 2-year disease-free and overall survivals were 36 and 48%, respectively. Treosulfan, etoposide and cyclophosphamide followed by AHSC has a favorable toxicity profile with low NRM and therefore represents a potential alternative regimen for ALL in 1. CR (NCT00682305).",
author = "Nicolaus Kr{\"o}ger and M Bornh{\"a}user and M Stelljes and U Pichlmeier and R Trenschel and C Schmid and R Arnold and H Martin and M Heinzelmann and C Wolschke and Meyer, {R G} and W Bethge and G Kobbe and Ayuketang, {Francis Ayuk} and N G{\"o}kbuget and D H{\"o}lzer and A Zander and D Beelen",
year = "2015",
month = dec,
doi = "10.1038/bmt.2015.202",
language = "English",
volume = "50",
pages = "1503--7",
journal = "BONE MARROW TRANSPL",
issn = "0268-3369",
publisher = "NATURE PUBLISHING GROUP",
number = "12",

}

RIS

TY - JOUR

T1 - Allogeneic stem cell transplantation after conditioning with treosulfan, etoposide and cyclophosphamide for patients with ALL: a phase II-study on behalf of the German Cooperative Transplant Study Group and ALL Study Group (GMALL)

AU - Kröger, Nicolaus

AU - Bornhäuser, M

AU - Stelljes, M

AU - Pichlmeier, U

AU - Trenschel, R

AU - Schmid, C

AU - Arnold, R

AU - Martin, H

AU - Heinzelmann, M

AU - Wolschke, C

AU - Meyer, R G

AU - Bethge, W

AU - Kobbe, G

AU - Ayuketang, Francis Ayuk

AU - Gökbuget, N

AU - Hölzer, D

AU - Zander, A

AU - Beelen, D

PY - 2015/12

Y1 - 2015/12

N2 - TBI-based preparative regimens are considered as standard conditioning therapy for allogeneic stem cell transplantation (AHSC) in patients with ALL. We investigated toxicity and efficacy of a non-TBI-based regimen consisting of treosulfan, etoposide and cyclophosphamide for ALL within a prospective study. Major inclusion criteria were CR and non-eligibility for TBI. Fifty patients with a median age of 46.5 years (range, 18-64) were included. Donors were HLA-identical sibling (n=8), matched (n=42) or mismatched (n=10) unrelated. The toxicity was moderate, resulting in a cumulative incidence of non-relapse mortality (NRM) at 1 year of 8% (90% confidence interval: 2-15%). Acute GvHD grade II-IV and grade III/IV was noted in 53% and 14%, respectively. Chronic GvHD at one year was seen in 41%. After a median follow-up of 24 months the cumulative incidence of relapse was 36% (90% confidence interval: 24-48) and 51% (90% confidence interval: 37-65) at 1 and 2 years, respectively. The estimated 2-year disease-free and overall survivals were 36 and 48%, respectively. Treosulfan, etoposide and cyclophosphamide followed by AHSC has a favorable toxicity profile with low NRM and therefore represents a potential alternative regimen for ALL in 1. CR (NCT00682305).

AB - TBI-based preparative regimens are considered as standard conditioning therapy for allogeneic stem cell transplantation (AHSC) in patients with ALL. We investigated toxicity and efficacy of a non-TBI-based regimen consisting of treosulfan, etoposide and cyclophosphamide for ALL within a prospective study. Major inclusion criteria were CR and non-eligibility for TBI. Fifty patients with a median age of 46.5 years (range, 18-64) were included. Donors were HLA-identical sibling (n=8), matched (n=42) or mismatched (n=10) unrelated. The toxicity was moderate, resulting in a cumulative incidence of non-relapse mortality (NRM) at 1 year of 8% (90% confidence interval: 2-15%). Acute GvHD grade II-IV and grade III/IV was noted in 53% and 14%, respectively. Chronic GvHD at one year was seen in 41%. After a median follow-up of 24 months the cumulative incidence of relapse was 36% (90% confidence interval: 24-48) and 51% (90% confidence interval: 37-65) at 1 and 2 years, respectively. The estimated 2-year disease-free and overall survivals were 36 and 48%, respectively. Treosulfan, etoposide and cyclophosphamide followed by AHSC has a favorable toxicity profile with low NRM and therefore represents a potential alternative regimen for ALL in 1. CR (NCT00682305).

U2 - 10.1038/bmt.2015.202

DO - 10.1038/bmt.2015.202

M3 - SCORING: Journal article

C2 - 26367236

VL - 50

SP - 1503

EP - 1507

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 12

ER -